

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Proposed Single Technology Appraisal (STA)

Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis  
(review of TA289) – [ID831]

### Provisional Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company(ies)</u></p> <ul style="list-style-type: none"> <li>• Novartis Pharmaceuticals (ruxolitinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• African Caribbean Leukaemia Trust</li> <li>• Anthony Nolan</li> <li>• Black Health Agency</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer52</li> <li>• Delete Blood cancer</li> <li>• Equalities National Council</li> <li>• Helen Rollason Cancer Charity</li> <li>• HAWC</li> <li>• Independent Cancer Patients Voice</li> <li>• Leukaemia Cancer Society</li> <li>• Leukaemia CARE</li> <li>• Lymphoma Association</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie Cancer Care</li> <li>• MPD Voice</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Rarer Cancers Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Surgical</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator company(ies)</u></p> <ul style="list-style-type: none"> <li>• Alan Pharmaceuticals (thalidomide)</li> <li>• Bristol-Myers Squibb (hydroxycarbamide)</li> <li>• Celgene (lenalidomide, thalidomide)</li> <li>• medac UK (hydroxycarbamide)</li> <li>• Nordic (hydroxycarbamide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Haematological Malignancies Group</li> <li>• Elimination of Leukaemia Fund</li> <li>• Health Research Authority</li> <li>• Institute of Cancer Research</li> <li>• <u>Leuka</u></li> <li>• Leukaemia &amp; Lymphoma Research</li> <li>• Leukaemia Busters</li> <li>• MRC Clinical Trials Unit</li> </ul>

<p>Oncology</p> <ul style="list-style-type: none"> <li>• British Committee for Standards in Haematology</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society for Haematology</li> <li>• Cancer Network Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Health Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Hammersmith and Fulham CCG</li> <li>• NHS South Norfolk CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <ul style="list-style-type: none"> <li>• <u>Evidence Review Group</u></li> <li>• NHS Centre for Reviews &amp; Dissemination and Centre for Health Economics - York</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales NHS Trust</li> </ul>
---	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

Definitions:

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non- company commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.

